Department of Endocrinology and Metabolism, Affiliated Hospital of Guilin Medical College, No. 15 Lequn Road, Guilin 541001, China.
Eur J Intern Med. 2012 Sep;23(6):e136-40. doi: 10.1016/j.ejim.2012.04.011. Epub 2012 May 15.
The relationship between ischemia-modified albumin (IMA) and thyroid dysfunction remains uncertain. This study aimed to investigate the influence of overt hypothyroidism (Oho), overt hyperthyroidism (Ohe), and their treatments on serum IMA levels.
A total of 35 untreated patients with Ohe, 35 untreated patients with Oho, and 35 control subjects were enrolled in the study. C-reactive protein (CRP), homocysteine (Hcy), IMA, and lipid profiles were measured and evaluated before and after treatment.
CRP, Hcy, and IMA levels and lipid profiles were higher in patients with Oho than in euthyroid or Ohe subjects (p<0.05). Basal IMA levels were reduced after treatments in all patients (p<0.05). In Ohe patients, serum IMA levels were positively correlated with free triiodothyronine (r=0.424, p=0.011) and free thyroxine (r=0.567, p<0.001) levels. In Oho patients, serum IMA levels were inversely correlated with free triiodothyronine (r=-0.555, p=0.001) and free thyroxine (r=-0.457, p=0.006) but positively correlated with anti-thyroid peroxidase antibody, C-reactive protein, and homocysteine levels (p<0.05). Linear regression analyses showed that free triiodothyronine was the most important factor affecting serum IMA levels in Ohe (β=0.694, p=0.019) and in Oho (β=-0.512, p=0.025).
IMA levels are increased in patients with thyroid dysfunction, particularly in overt hypothyroidism. Thyroid dysfunction has a significant impact on the oxidative stress status.
缺血修饰白蛋白（IMA）与甲状腺功能障碍之间的关系仍不确定。本研究旨在探讨显性甲状腺功能减退症（Oho）、显性甲状腺功能亢进症（Ohe）及其治疗对血清 IMA 水平的影响。
共纳入 35 例未经治疗的 Ohe 患者、35 例未经治疗的 Oho 患者和 35 例对照者。测定并评估治疗前后 C 反应蛋白（CRP）、同型半胱氨酸（Hcy）、IMA 和血脂谱。
Oho 患者的 CRP、Hcy 和 IMA 水平及血脂谱均高于甲状腺功能正常或 Ohe 患者（p<0.05）。所有患者治疗后基础 IMA 水平均降低（p<0.05）。在 Ohe 患者中，血清 IMA 水平与游离三碘甲状腺原氨酸（r=0.424，p=0.011）和游离甲状腺素（r=0.567，p<0.001）水平呈正相关。在 Oho 患者中，血清 IMA 水平与游离三碘甲状腺原氨酸（r=-0.555，p=0.001）和游离甲状腺素（r=-0.457，p=0.006）呈负相关，但与抗甲状腺过氧化物酶抗体、CRP 和同型半胱氨酸水平呈正相关（p<0.05）。线性回归分析显示，游离三碘甲状腺原氨酸是 Ohe（β=0.694，p=0.019）和 Oho（β=-0.512，p=0.025）患者影响血清 IMA 水平的最重要因素。
甲状腺功能障碍患者的 IMA 水平升高，尤其是显性甲状腺功能减退症患者。甲状腺功能障碍对氧化应激状态有显著影响。
